Financial Analysis: Cryo-Cell International (OTCMKTS:CCEL) Vs. Lisata Therapeutics (NASDAQ:LSTA)
Financial Analysis: Cryo-Cell International (OTCMKTS:CCEL) Vs. Lisata Therapeutics (NASDAQ:LSTA)
Cryo-Cell International (OTCMKTS:CCEL – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.
冷凍細胞國際(場外交易代碼：CEL-GET評級)和麗莎塔治療(納斯達克：LSTA-GET評級)都是小盤醫療公司，但哪種投資更好？我們將根據這兩家公司的機構所有權、股息、估值、風險、盈利能力、收益和分析師的建議來比較它們的實力。
Profitability
盈利能力
This table compares Cryo-Cell International and Lisata Therapeutics' net margins, return on equity and return on assets.
下表比較了冷凍細胞國際公司和麗莎塔治療公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Cryo-Cell International | 4.34% | 49.62% | 2.18% |
| Lisata Therapeutics | N/A | -29.53% | -27.96% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 國際冷凍細胞公司 | 4.34% | 49.62% | 2.18% |
| 利薩塔治療公司 | 不適用 | -29.53% | -27.96% |
Earnings & Valuation
收益與估值
This table compares Cryo-Cell International and Lisata Therapeutics' gross revenue, earnings per share and valuation.
此表比較了冷凍細胞國際公司和李薩塔治療公司的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cryo-Cell International | $28.89 million | 1.44 | $2.08 million | $0.15 | 32.67 |
| Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.34 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 國際冷凍細胞公司 | 2,889萬美元 | 1.44 | 208萬美元 | $0.15 | 32.67 |
| 利薩塔治療公司 | 不適用 | 不適用 | -2,747萬元 | ($12.23) | -0.34 |
Analyst Recommendations
分析師建議
This is a breakdown of current ratings for Cryo-Cell International and Lisata Therapeutics, as provided by MarketBeat.
這是由MarketBeat提供的冷凍細胞國際公司和李薩塔治療公司的當前評級細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cryo-Cell International | 0 | 0 | 1 | 0 | 3.00 |
| Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 國際冷凍細胞公司 | 0 | 0 | 1 | 0 | 3.00 |
| 利薩塔治療公司 | 0 | 0 | 2 | 0 | 3.00 |
Cryo-Cell International currently has a consensus target price of $12.00, indicating a potential upside of 144.90%. Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 259.71%. Given Lisata Therapeutics' higher probable upside, analysts plainly believe Lisata Therapeutics is more favorable than Cryo-Cell International.
CRYO-CELL國際公司目前的普遍目標價為12美元，這意味着潛在的上行空間為144.90%。利薩塔治療公司的共識目標價為15美元，表明潛在漲幅為259.71%。鑑於李薩塔治療公司更有可能上行，分析人士明確認為，利薩塔治療公司比冷凍細胞國際公司更有利。
Volatility and Risk
波動性和風險
Cryo-Cell International has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
Cryo-Cell International的貝塔係數為0.35，這意味着其股價的波動性比標準普爾500指數低65%。相比之下，利薩塔治療公司的貝塔指數為1.04，這意味着其股價的波動性比標準普爾500指數高出4%。
Institutional and Insider Ownership
機構和內部人持股
9.0% of Cryo-Cell International shares are owned by institutional investors. Comparatively, 15.6% of Lisata Therapeutics shares are owned by institutional investors. 33.8% of Cryo-Cell International shares are owned by company insiders. Comparatively, 2.2% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Cryo-Cell International 9.0%的股份由機構投資者持有。相比之下，李薩塔治療公司15.6%的股份由機構投資者持有。Cryo-Cell International 33.8%的股份由公司內部人士持有。相比之下，李薩塔治療公司2.2%的股份由公司內部人士持有。強大的機構持股表明，對衝基金、大型基金管理公司和捐贈基金相信，一隻股票的長期表現將好於大盤。
Summary
摘要
Cryo-Cell International beats Lisata Therapeutics on 8 of the 12 factors compared between the two stocks.
在兩隻股票之間的12個因素中，冷凍細胞國際公司在8個因素上擊敗了裏薩塔治療公司。
About Cryo-Cell International
關於冷凍細胞國際公司
(Get Rating)
(獲取評級)
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
國際冷凍細胞公司致力於細胞加工和低温細胞存儲，專注於收集和保存供家庭使用的臍帶血幹細胞。它提供臍帶組織服務，存儲部分臍帶組織，臍帶組織是間充質幹細胞的來源，用於再生醫學，用於治療一系列疾病，包括心臟、腎臟疾病、肌萎縮側索硬化症、傷口癒合和自身免疫性疾病。該公司還製造和銷售PrepaCyte CB處理系統，這是一種用於處理臍帶血幹細胞的技術。它在全球儲存了大約500,000個臍帶血和臍帶組織幹細胞。該公司直接向準父母推銷其臍帶血幹細胞保存服務，並通過產科醫生、兒科醫生、分娩教育人員、認證護士助產士和其他相關醫療保健專業人員分發信息。CRYO-CELL國際公司成立於1989年，總部設在佛羅裏達州奧茲馬市。
About Lisata Therapeutics
關於李薩塔治療公司
(Get Rating)
(獲取評級)
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
利薩塔治療公司是一家臨牀階段的生物製藥公司，專注於開發細胞療法並將其商業化，以逆轉疾病和/或促進受損組織的再生。它的候選產品包括接受Sakigake指定的HONEDRA，用於治療嚴重肢體缺血的第二階段臨牀試驗；XOWNA，用於治療冠狀動脈微血管功能障礙的第二階段臨牀試驗；以及CLBS201，一種用於治療慢性腎臟疾病透析前患者的CD34+細胞療法。該公司前身為NeoStem，Inc.，並於2015年6月更名為Caladrius Biosciences，Inc.。該公司前身為Caladrius Biosciences，Inc.，並於2022年9月15日更名為李薩塔治療公司。利薩塔治療公司成立於1980年，總部設在新澤西州的巴斯金裏奇。
Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.
接受《冷凍細胞國際日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cryo-Cell International和相關公司的最新新聞和分析師評級的每日簡要摘要。